Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a top… Read more
Grace Therapeutics, Inc. (GRCE) - Total Liabilities
Latest total liabilities as of September 2025: $3.76 Million USD
Based on the latest financial reports, Grace Therapeutics, Inc. (GRCE) has total liabilities worth $3.76 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Grace Therapeutics, Inc. - Total Liabilities Trend (2010–2025)
This chart illustrates how Grace Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Grace Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Grace Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GreenMobility A/S
CO:GREENM
|
Denmark | Dkr139.33 Million |
|
Nasmed Ozel Saglik Hizmetleri Ticaret AS
IS:EGEPO
|
Turkey | TL303.09 Million |
|
Victoria Investama Tbk
JK:VICO
|
Indonesia | Rp29.92 Trillion |
|
Seafco Public Company Limited
BK:SEAFCO
|
Thailand | ฿925.07 Million |
|
Taiwan Takisawa Technology Co Ltd
TWO:6609
|
Taiwan | NT$1.05 Billion |
|
Zimmite Taiwan Ltd
TWO:8435
|
Taiwan | NT$140.55 Million |
|
Principal Capital Public Company Limited
BK:PRINC
|
Thailand | ฿5.47 Billion |
|
Whiting Petroleum Corporation
PINK:WLLBW
|
USA | $4.45 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down Grace Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Grace Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Grace Therapeutics, Inc. (2010–2025)
The table below shows the annual total liabilities of Grace Therapeutics, Inc. from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $5.38 Million | -53.42% |
| 2024-03-31 | $11.56 Million | +3.48% |
| 2023-03-31 | $11.17 Million | -45.12% |
| 2022-03-31 | $20.35 Million | +199.35% |
| 2021-03-31 | $6.80 Million | -31.05% |
| 2020-03-31 | $9.86 Million | -61.86% |
| 2019-03-31 | $25.85 Million | +126.56% |
| 2018-03-31 | $11.41 Million | +1092.12% |
| 2016-03-31 | $957.12K | -69.91% |
| 2015-03-31 | $3.18 Million | -71.35% |
| 2014-03-31 | $11.10 Million | +364.58% |
| 2013-03-31 | $2.39 Million | +88.63% |
| 2012-03-31 | $1.27 Million | -75.83% |
| 2011-03-31 | $5.24 Million | +7.35% |
| 2010-03-31 | $4.88 Million | -- |